Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.17
GNC's Cash to Debt is ranked higher than
53% of the 484 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.83 vs. GNC: 0.17 )
GNC' s 10-Year Cash to Debt Range
Min: 0.04   Max: 0.18
Current: 0.17

0.04
0.18
Equity to Asset 0.30
GNC's Equity to Asset is ranked higher than
53% of the 482 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. GNC: 0.30 )
GNC' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.4
Current: 0.3

0.23
0.4
F-Score: 6
Z-Score: 3.38
M-Score: -2.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 17.51
GNC's Operating margin (%) is ranked higher than
98% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.80 vs. GNC: 17.51 )
GNC' s 10-Year Operating margin (%) Range
Min: 10.24   Max: 17.61
Current: 17.51

10.24
17.61
Net-margin (%) 10.08
GNC's Net-margin (%) is ranked higher than
97% of the 486 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.37 vs. GNC: 10.08 )
GNC' s 10-Year Net-margin (%) Range
Min: 3.3   Max: 10.08
Current: 10.08

3.3
10.08
ROE (%) 32.49
GNC's ROE (%) is ranked higher than
97% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.99 vs. GNC: 32.49 )
GNC' s 10-Year ROE (%) Range
Min: 8.36   Max: 32.49
Current: 32.49

8.36
32.49
ROA (%) 9.67
GNC's ROA (%) is ranked higher than
93% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.42 vs. GNC: 9.67 )
GNC' s 10-Year ROA (%) Range
Min: 2.38   Max: 9.67
Current: 9.67

2.38
9.67
ROC (Joel Greenblatt) (%) 65.32
GNC's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 485 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.02 vs. GNC: 65.32 )
GNC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 35.18   Max: 69.2
Current: 65.32

35.18
69.2
Revenue Growth (%) 9.60
GNC's Revenue Growth (%) is ranked higher than
86% of the 330 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.90 vs. GNC: 9.60 )
GNC' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 9.6
Current: 9.6

0
9.6
EBITDA Growth (%) 21.70
GNC's EBITDA Growth (%) is ranked higher than
93% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.00 vs. GNC: 21.70 )
GNC' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 21.7
Current: 21.7

0
21.7
EPS Growth (%) 47.40
GNC's EPS Growth (%) is ranked higher than
98% of the 297 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. GNC: 47.40 )
GNC' s 10-Year EPS Growth (%) Range
Min: 0   Max: 58.1
Current: 47.4

0
58.1
» GNC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

GNC Guru Trades in Q1 2013

Mario Gabelli 5,400 sh (New)
Louis Moore Bacon 222,725 sh (New)
Steven Cohen 4,276,960 sh (+2429.62%)
RS Investment Management 1,042,720 sh (+1288.44%)
Caxton Associates 30,000 sh (+233.33%)
Joel Greenblatt 100,048 sh (+92.61%)
Jim Simons 989,700 sh (+47.25%)
Columbia Wanger 2,569,200 sh (+4.36%)
Pioneer Investments Sold Out
Paul Tudor Jones 5,500 sh (-21.43%)
» More
Q2 2013

GNC Guru Trades in Q2 2013

John Keeley 151,580 sh (New)
Mario Gabelli 11,400 sh (+111.11%)
Louis Moore Bacon 329,000 sh (+47.72%)
Columbia Wanger 2,569,200 sh (unchged)
Caxton Associates Sold Out
Paul Tudor Jones Sold Out
RS Investment Management 994,115 sh (-4.66%)
Joel Greenblatt 83,905 sh (-16.14%)
Steven Cohen 2,553,811 sh (-40.29%)
Jim Simons 128,700 sh (-87%)
» More
Q3 2013

GNC Guru Trades in Q3 2013

Jim Simons 320,100 sh (+148.72%)
John Keeley 209,580 sh (+38.26%)
Steven Cohen 2,691,891 sh (+5.41%)
Columbia Wanger 2,569,200 sh (unchged)
Mario Gabelli 11,400 sh (unchged)
Louis Moore Bacon Sold Out
RS Investment Management 804,598 sh (-19.06%)
Joel Greenblatt 49,230 sh (-41.33%)
» More
Q4 2013

GNC Guru Trades in Q4 2013

Paul Tudor Jones 27,563 sh (New)
Caxton Associates 6,344 sh (New)
Joel Greenblatt 155,608 sh (+216.08%)
Columbia Wanger 2,569,200 sh (unchged)
John Keeley 209,030 sh (-0.26%)
Mario Gabelli 10,500 sh (-7.89%)
RS Investment Management 695,403 sh (-13.57%)
Jim Simons 122,500 sh (-61.73%)
Steven Cohen 321,936 sh (-88.04%)
» More
» Details

Insider Trades

Latest Guru Trades with GNC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Add 216.08%0.15%$53 - $60.56 $ 45.23-22%155608
Joel Greenblatt 2013-09-30 Reduce -41.33%0.07%$45.88 - $54.5 $ 45.23-12%49230
John Keeley 2013-09-30 Add 38.26%0.06%$45.88 - $54.5 $ 45.23-12%209580
John Keeley 2013-06-30 New Buy0.13%$38.88 - $47.93 $ 45.232%151580
Mario Gabelli 2013-06-30 Add 111.11%$38.88 - $47.93 $ 45.232%11400
Joel Greenblatt 2013-03-31 Add 92.61%0.1%$32.2 - $42.19 $ 45.2320%100048
Mario Gabelli 2013-03-31 New Buy$32.2 - $42.19 $ 45.2320%5400
Joel Greenblatt 2012-12-31 Add 135.04%0.06%$32.6 - $40.72 $ 45.2325%51943
Joel Greenblatt 2012-09-30 New Buy0.06%$35.74 - $42.41 $ 45.2316%22100
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.40
GNC's P/E(ttm) is ranked higher than
74% of the 432 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.70 vs. GNC: 16.40 )
GNC' s 10-Year P/E(ttm) Range
Min: 14.27   Max: 31.9
Current: 16.4

14.27
31.9
P/B 5.00
GNC's P/B is ranked lower than
64% of the 471 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.70 vs. GNC: 5.00 )
GNC' s 10-Year P/B Range
Min: 2.17   Max: 6.88
Current: 5

2.17
6.88
P/S 1.70
GNC's P/S is ranked lower than
75% of the 490 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.46 vs. GNC: 1.70 )
GNC' s 10-Year P/S Range
Min: 0.92   Max: 2.3
Current: 1.7

0.92
2.3
PFCF 23.50
GNC's PFCF is ranked higher than
63% of the 298 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.50 vs. GNC: 23.50 )
GNC' s 10-Year PFCF Range
Min: 12.82   Max: 34.5
Current: 23.5

12.82
34.5
EV-to-EBIT 12.00
GNC's EV-to-EBIT is ranked higher than
71% of the 457 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.48 vs. GNC: 12.00 )
GNC' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 15.2
Current: 12

9.8
15.2
PEG 0.80
GNC's PEG is ranked higher than
87% of the 240 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.29 vs. GNC: 0.80 )
GNC' s 10-Year PEG Range
Min: 0   Max: 0.8
Current: 0.8

0
0.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
GNC's Dividend Yield is ranked lower than
65% of the 408 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.88 vs. GNC: 1.40 )
GNC' s 10-Year Dividend Yield Range
Min: 0.27   Max: 1.36
Current: 1.4

0.27
1.36
Dividend Payout 0.22
GNC's Dividend Payout is ranked higher than
81% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. GNC: 0.22 )
GNC' s 10-Year Dividend Payout Range
Min: 0.19   Max: 0.22
Current: 0.22

0.19
0.22
Yield on cost (5-Year) 1.40
GNC's Yield on cost (5-Year) is ranked lower than
67% of the 415 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. GNC: 1.40 )
GNC' s 10-Year Yield on cost (5-Year) Range
Min: 0.27   Max: 1.36
Current: 1.4

0.27
1.36
Share Buyback Rate -3.10
GNC's Share Buyback Rate is ranked higher than
66% of the 271 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.10 vs. GNC: -3.10 )
GNC' s 10-Year Share Buyback Rate Range
Min: 0   Max: -6.1
Current: -3.1

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
GNC's Price/Median PS Value is ranked higher than
82% of the 460 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. GNC: 1.00 )
GNC' s 10-Year Price/Median PS Value Range
Min: 0.82   Max: 1.24
Current: 1

0.82
1.24
Earnings Yield (Greenblatt) 8.30
GNC's Earnings Yield (Greenblatt) is ranked higher than
74% of the 467 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. GNC: 8.30 )
GNC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.6   Max: 10.2
Current: 8.3

6.6
10.2

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare: » details
Traded in other countries:IGN.Germany
GNC Holdings Inc is a global specialty retailer of health and wellness products, including VMHS products, sports nutrition products, and diet products. The Company's business segments include: Retail, Franchising and Manufacturing/Wholesale.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide